BR112023005152A2 - Anticorpo biespecífico com especificidade intensificada (seba) - Google Patents
Anticorpo biespecífico com especificidade intensificada (seba)Info
- Publication number
- BR112023005152A2 BR112023005152A2 BR112023005152A BR112023005152A BR112023005152A2 BR 112023005152 A2 BR112023005152 A2 BR 112023005152A2 BR 112023005152 A BR112023005152 A BR 112023005152A BR 112023005152 A BR112023005152 A BR 112023005152A BR 112023005152 A2 BR112023005152 A2 BR 112023005152A2
- Authority
- BR
- Brazil
- Prior art keywords
- seba
- bispecific antibody
- binding specificity
- enhanced specificity
- terminus
- Prior art date
Links
- 102000009465 Growth Factor Receptors Human genes 0.000 abstract 1
- 108010009202 Growth Factor Receptors Proteins 0.000 abstract 1
- 101000851181 Homo sapiens Epidermal growth factor receptor Proteins 0.000 abstract 1
- 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 abstract 1
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 230000008472 epithelial growth Effects 0.000 abstract 1
- 102000045108 human EGFR Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Abstract
ANTICORPO BIESPECÍFICO COM ESPECIFICIDADE INTENSIFICADA (SEBA). A presente invenção refere-se a anticorpo tetravalente biespecífico com uma especificidade de ligação a um receptor do fator de crescimento epitelial humano (EGFR), compreendendo, do N-terminal para o C-terminal, uma região Fab com uma primeira especificidade de ligação pelo EGFR humano, sendo que a região Fab compreende uma região variável que liga um sequência de aminoácidos com ao menos 90% de identidade de sequência com as sequências aqui divulgadas; um domínio Fc e um domínio scFv com uma segunda especificidade de ligação pelo HER3.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063081315P | 2020-09-21 | 2020-09-21 | |
| US202063109877P | 2020-11-05 | 2020-11-05 | |
| PCT/US2021/051164 WO2022061255A1 (en) | 2020-09-21 | 2021-09-21 | Specificity enchanced bispecific antibody (seba) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023005152A2 true BR112023005152A2 (pt) | 2023-04-25 |
Family
ID=80775654
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023005152A BR112023005152A2 (pt) | 2020-09-21 | 2021-09-21 | Anticorpo biespecífico com especificidade intensificada (seba) |
| BR112023005138A BR112023005138A2 (pt) | 2020-09-21 | 2021-09-21 | Complexo de ligação a egfr e método de preparação e uso do mesmo |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023005138A BR112023005138A2 (pt) | 2020-09-21 | 2021-09-21 | Complexo de ligação a egfr e método de preparação e uso do mesmo |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230374157A1 (pt) |
| EP (2) | EP4213880A1 (pt) |
| JP (2) | JP2023542336A (pt) |
| KR (2) | KR20230117330A (pt) |
| AU (2) | AU2021344531A1 (pt) |
| BR (2) | BR112023005152A2 (pt) |
| CA (2) | CA3196014A1 (pt) |
| IL (2) | IL301473A (pt) |
| MX (2) | MX2023003303A (pt) |
| TW (2) | TW202222824A (pt) |
| WO (2) | WO2022061255A1 (pt) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021178253A1 (en) * | 2020-03-03 | 2021-09-10 | Systimmune, Inc. | Anti-cd19 antibodies and methods of using and making thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6282745B2 (ja) * | 2013-09-12 | 2018-02-21 | ハロザイム インコーポレイテッド | 修飾抗上皮成長因子受容体抗体およびその使用法 |
| EP4050026A1 (en) * | 2014-04-01 | 2022-08-31 | Adimab, LLC | Method of obtaining or identifying one or more common light chains for use in preparing a multispecific antibody |
| KR102590385B1 (ko) * | 2014-12-22 | 2023-10-18 | 시스트이뮨, 인코포레이티드 | 이중특이적 4가 항체 및 이의 제조 및 사용방법 |
| US11326182B2 (en) * | 2016-04-29 | 2022-05-10 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
-
2021
- 2021-09-21 IL IL301473A patent/IL301473A/en unknown
- 2021-09-21 JP JP2023518078A patent/JP2023542336A/ja active Pending
- 2021-09-21 KR KR1020237012856A patent/KR20230117330A/ko unknown
- 2021-09-21 MX MX2023003303A patent/MX2023003303A/es unknown
- 2021-09-21 IL IL301472A patent/IL301472A/en unknown
- 2021-09-21 US US18/027,569 patent/US20230374157A1/en active Pending
- 2021-09-21 CA CA3196014A patent/CA3196014A1/en active Pending
- 2021-09-21 JP JP2023518081A patent/JP2023542337A/ja active Pending
- 2021-09-21 WO PCT/US2021/051164 patent/WO2022061255A1/en active Application Filing
- 2021-09-21 EP EP21870389.0A patent/EP4213880A1/en active Pending
- 2021-09-21 CA CA3196015A patent/CA3196015A1/en active Pending
- 2021-09-21 EP EP21870390.8A patent/EP4214238A2/en active Pending
- 2021-09-21 AU AU2021344531A patent/AU2021344531A1/en active Pending
- 2021-09-21 AU AU2021345349A patent/AU2021345349A1/en active Pending
- 2021-09-21 WO PCT/US2021/051165 patent/WO2022061256A2/en active Application Filing
- 2021-09-21 BR BR112023005152A patent/BR112023005152A2/pt unknown
- 2021-09-21 MX MX2023003304A patent/MX2023003304A/es unknown
- 2021-09-21 BR BR112023005138A patent/BR112023005138A2/pt unknown
- 2021-09-21 KR KR1020237012857A patent/KR20230117331A/ko unknown
- 2021-09-22 TW TW110135157A patent/TW202222824A/zh unknown
- 2021-09-22 TW TW110135136A patent/TW202300529A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3196015A1 (en) | 2022-03-24 |
| WO2022061255A1 (en) | 2022-03-24 |
| BR112023005138A2 (pt) | 2023-04-25 |
| JP2023542336A (ja) | 2023-10-06 |
| CA3196014A1 (en) | 2022-03-24 |
| KR20230117330A (ko) | 2023-08-08 |
| KR20230117331A (ko) | 2023-08-08 |
| AU2021344531A1 (en) | 2023-05-18 |
| JP2023542337A (ja) | 2023-10-06 |
| WO2022061256A9 (en) | 2022-12-22 |
| EP4213880A1 (en) | 2023-07-26 |
| US20230374157A1 (en) | 2023-11-23 |
| IL301472A (en) | 2023-05-01 |
| MX2023003304A (es) | 2023-05-09 |
| AU2021345349A1 (en) | 2023-05-11 |
| TW202300529A (zh) | 2023-01-01 |
| IL301473A (en) | 2023-05-01 |
| WO2022061256A2 (en) | 2022-03-24 |
| EP4214238A2 (en) | 2023-07-26 |
| MX2023003303A (es) | 2023-05-09 |
| TW202222824A (zh) | 2022-06-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20191463A1 (es) | Anticuerpos biespecificos de union especifica pd1 y lag3 | |
| BR112014001573B8 (pt) | Molécula fv ao antígeno multivalente | |
| MD3428194T2 (ro) | Moleculă polipeptidică cu specificitate duală îmbunătățită | |
| NZ724904A (en) | Hybrid immunoglobulin containing non-peptidyl linkage | |
| AR078254A1 (es) | Inmunoglobulinas con dominio variable dual y usos de las mismas | |
| BR112016011025A8 (pt) | anticorpo humanizado anti calicreina-2. | |
| CL2021000517A1 (es) | Anticuerpo etiquetado y/o fragmento del mismo que comprende un anticuerpo monoclonal o un fragmento del mismo, que se une específicamente a tau humano; ácido nucleico que lo codifica; vector; célula; método para producir anticuerpo; y uso de los mismos para inhibir la agregación de tau, y enfermedades asociadas (divisional de la solicitud no. 202001003) | |
| PE20190737A1 (es) | Anticuerpos anti-cd27 | |
| MX2014014801A (es) | Metodo para la seleccion y produccion de entidades dirigidas altamente selectivas hechas a la medida y multiespecificas que contienen por lo menos dos entidades de union diferentes y usos de las mismas. | |
| AR077088A1 (es) | Proteinas biespecificas de union a antigeno | |
| PE20120475A1 (es) | Anticuerpos especificos para dkk-1 | |
| MX360155B (es) | Anticuerpos que se unen al ligando 1a tipo tnf y sus usos. | |
| MX2022002342A (es) | Composiciones y metodos para suministro de acidos nucleicos a celulas. | |
| EA201691780A1 (ru) | Наноструктурированный песок, способ получения наноструктурированного песка, способ разделения смеси загрязняющее вещество-вода с помощью наноструктурированного песка и дополнительные применения | |
| BR112022011669A2 (pt) | Anticorpos biespecíficos caninizados e parceiros de ligação biespecíficos para tratar dermatite atópica | |
| PH12020500058A1 (en) | Novel anti-human ceacam5 antibody fab fragment | |
| EA201691782A1 (ru) | Антитела, специфические к рецептору инсулиноподобного фактора роста 1, и их применения | |
| PE20181199A1 (es) | Anticuerpos que se unen al receptor cannabinoide 1 (cb1) humano | |
| BR112021026089A2 (pt) | Fragmentos de ligação ao antígeno de cd3 e composições compreendendo os mesmos | |
| BR112023005152A2 (pt) | Anticorpo biespecífico com especificidade intensificada (seba) | |
| BR112018072140A2 (pt) | anticorpos anti-basigin humanizados e uso dos mesmos | |
| MX2021005048A (es) | Anticuerpos anti-ctla4, fragmentos de anticuerpos, sus inmunoconjugados y usos. | |
| CR20220415A (es) | Anticuerpos multiespecíficos, composiciones que los comprenden, y vectores y usos de los mismos | |
| EA202191231A1 (ru) | СПОСОБЫ ЛЕЧЕНИЯ ЭНДОКРИННОЙ ОФТАЛЬМОПАТИИ С ПРИМЕНЕНИЕМ АНТИ-FcRn АНТИТЕЛ | |
| PE20231504A1 (es) | Anticuerpos especificos para kras y sus usos |